Video+

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

Deep Dutta, from New Delhi, talks about the implications of the D2d trial findings for doctors practicing in India (2:51).

With all three RISE studies now published, John Wilding reflects on the pathophysiological differences between children and adults with type 2 diabetes (2:12).

John Wilding talks about research presented at the ADA Scientific Sessions looking at the management of type 1 diabetes in elite athletes (3:18).

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).

Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

PIONEER 6 lead investigator Mansoor Husain discusses the results of the trial, and how oral and injectable semaglutide compare and can be used in the clinic (4:40).

Lori Berard gives an overview of the ADA session “Making a difference in five minutes: Interventions in diabetes for anyone.” (2:00)

Stephanie Amiel overviews her ADA highlights, including novel rapid-acting insulins and the sometimes surprising insights that technology offers into hypoglycemia (3:20).

Nurse educator Lori Berard gives her view of how the REWIND trial can help clinicians working with people with type 2 diabetes (1:48).

John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).

Kim Pfotenhauer considers whether the D2d trial has settled the question of the role of vitamin D in the prevention of type 2 diabetes (1:53).

In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

Psychological Wellbeing Practitioner Abeni Lüken outlines the patient engagement techniques that healthcare practitioners can use to facilitate open and positive discussions about eating disorders (4:08).

Roy Taylor explains why the DiRECT intervention may benefit a surprisingly wide variety of people, and how the trial’s findings could trigger a major shift in thinking about how to tackle type 2 diabetes (6:45).

Amar Puttanna highlights the key clinical messages that have come out of the DiRECT trial (0:59).